SB 265610

Drug Profile

SB 265610

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories
  • Mechanism of Action Interleukin 8 receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 04 Feb 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (PO)
  • 09 Jun 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Inflammatory Bowel Disorders pharmacodynamics section
  • 31 Dec 2001 A preclinical study has been added to the Inflammatory Bowel Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top